Logo

RNA

Avidity Biosciences, Inc.

RNA

Avidity Biosciences, Inc. • NASDAQ
$71.70 ▲ 0.20% (+0.14)
Market Cap $9.41 B
52w High $71.78
52w Low $21.51
Dividend Yield 0%
P/E -17.11
Volume 1.07M
Outstanding Shares 131.25M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $12.475M ▲ $201.281M ▲ $-174.442M ▼ -1.398K% ▲ $-1.27 ▼ $-173.386M ▼
Q2-2025 $3.847M ▲ $36.864M ▼ $-157.315M ▼ -4.089K% ▲ $-1.21 ▼ $-170.328M ▼
Q1-2025 $1.573M ▼ $133.09M ▲ $-115.773M ▼ -7.36K% ▼ $-0.9 ▼ $-130.732M ▼
Q4-2024 $2.973M ▲ $123.963M ▲ $-102.257M ▼ -3.44K% ▲ $-0.8 ▼ $-120.252M ▼
Q3-2024 $2.336M $100.47M $-80.398M -3.442K% $-0.65 $-97.424M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.876B ▲ $2.134B ▲ $247.944M ▲ $1.886B ▲
Q2-2025 $1.183B ▼ $1.369B ▼ $176.262M ▲ $1.193B ▼
Q1-2025 $1.38B ▼ $1.459B ▼ $130.352M ▼ $1.329B ▼
Q4-2024 $1.501B ▼ $1.564B ▼ $138.936M ▲ $1.425B ▼
Q3-2024 $1.589B $1.641B $137.391M $1.503B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-174.442M ▼ $-156.173M ▲ $-587.926M ▼ $850.366M ▲ $106.251M ▲ $-160.06M ▲
Q2-2025 $-157.315M ▼ $-199.666M ▼ $185.485M ▲ $3.773M ▲ $-10.293M ▼ $-203.009M ▼
Q1-2025 $-115.773M ▼ $-124.829M ▼ $157.188M ▲ $1.937M ▼ $34.335M ▲ $-128.582M ▼
Q4-2024 $-102.257M ▼ $-99.871M ▼ $-64.172M ▲ $13.724M ▼ $-150.319M ▲ $-103.787M ▼
Q3-2024 $-80.397M $-65.615M $-482.413M $342.464M $-205.564M $-67.319M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025
Reportable Segment
Reportable Segment
 $0 ▲$0 ▲$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement RNA is still a pure R&D‑stage biotech, so it effectively has no product revenue yet. The income statement is driven almost entirely by research and development and related operating expenses. Losses have grown over time as the company has scaled up its clinical programs, hired more staff, and advanced multiple drug candidates. That pattern is typical for a clinical‑stage biotech that is moving from early research into larger and more complex trials. There is no sign yet of operating leverage or profitability, and that will not realistically change until at least one program is approved and commercialized, or meaningful partnership revenue ramps up. The key takeaway: the business is built around spending heavily today in hopes of future upside; current financial performance is intentionally loss‑making and will likely stay that way for several years, with results very sensitive to R&D pace and any milestone or collaboration payments.

Balance Sheet

Balance Sheet The balance sheet shows a company that has strengthened its resource base over the past few years while keeping debt very modest. Total assets and shareholder equity have grown meaningfully, which likely reflects equity raises and upfront or milestone payments from partnerships. Cash has also increased recently, giving RNA a multi‑year operating runway by management’s own guidance. On the other side, financial debt is very small relative to equity, so the capital structure is conservative and not highly leveraged. The main risk factor is not the current balance sheet health, but the fact that the asset base is dominated by cash and early‑stage R&D rather than approved products or recurring revenue. Over time, the company will probably need either successful drugs, more partnerships, or additional equity financing to maintain this strength.

Cash Flow

Cash Flow Cash flow is clearly negative, as expected for a company funding multiple clinical programs without commercial products. Operating cash outflows have been rising as RNA increases spending on trials, manufacturing scale‑up, and platform expansion. Free cash flow closely tracks operating cash flow because capital spending needs have been relatively small so far. The encouraging point is that the current cash balance appears sufficient to support operations for several years under current plans, reducing immediate financing pressure. The flip side is that, unless there are major partnership inflows or an approved product, the company will likely continue burning cash for an extended period, and future capital raises remain a possibility.

Competitive Edge

Competitive Edge RNA has carved out a focused and differentiated niche within RNA therapeutics by targeting delivery to muscle and potentially other non‑liver tissues, an area that has historically been very challenging. Its AOC platform, early clinical success in delivering RNA to muscle, and focus on rare neuromuscular diseases give it a first‑mover advantage in a specific but meaningful slice of the market. Strategic collaborations with large pharmaceutical companies add validation, technical support, and financial resources, which can be important competitive strengths. However, the broader RNA and genetic medicine space is crowded and fast‑moving. Large, well‑funded competitors and emerging platforms could narrow RNA’s lead over time. The company’s ultimate competitive position will depend heavily on how its clinical data, safety profile, dosing convenience, and eventual pricing compare to other approaches as they mature.

Innovation and R&D

Innovation and R&D Innovation is the core of RNA’s story. Its AOC platform is designed as a modular “plug‑and‑play” system that combines antibodies with RNA molecules to reach specific tissues, especially muscle. This addresses one of the biggest technical bottlenecks in RNA medicine: getting therapies beyond the liver. The company’s pipeline is concentrated in serious rare muscle diseases, where there are few or no treatments that target the root cause. Lead programs are already in mid‑ to late‑stage clinical trials, including a Phase 3 effort, which marks a significant step up from early proof‑of‑concept work. RNA is also working on next‑generation versions of its technology and extending it into cardiology and immunology, which could broaden the platform’s impact if successful. The opportunity is substantial, but so is the risk: clinical‑stage biotech R&D is inherently uncertain. Any safety signals, weaker‑than‑expected efficacy, trial delays, or regulatory setbacks could materially affect the value of specific programs and the perceived strength of the platform.

Summary

RNA is a classic high‑risk, high‑potential clinical‑stage biotech built around a novel RNA delivery platform. Financially, the company is in heavy investment mode: almost no product revenue, sizeable and growing operating losses, and consistent negative cash flow. The balance sheet, however, is currently solid, with a sizeable cash cushion and minimal debt, providing room to pursue its clinical agenda over the next few years without immediate refinancing pressure. Strategically, RNA’s edge lies in its targeted AOC technology, early proof of muscle delivery, and focus on rare diseases with significant unmet need, supported by partnerships with major pharmaceutical companies. Success of its late‑stage programs and expansion into new disease areas could be transformative, but outcomes remain highly uncertain given the usual clinical, regulatory, and competitive risks in cutting‑edge biotech. Overall, this is an early‑revenue company whose value is driven far more by scientific and clinical milestones than by current financial results, with balance‑sheet strength providing time to see whether the platform delivers on its promise.

NEWS

November 19, 2025 · 9:13 AM UTC

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

Read more

November 10, 2025 · 4:05 PM UTC

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Read more

October 28, 2025 · 2:42 PM UTC

RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders

Read more

October 28, 2025 · 1:55 PM UTC

Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders

Read more

October 28, 2025 · 6:40 AM UTC

RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders

Read more